

1 **The risk and risk factors of chikungunya virus infection and rheumatological**
2 **sequelae in a cohort of U.S. Military Health System beneficiaries: implications**
3 **for the vaccine era**
4

5 Pollett SD^{1,2*}, Hsieh H-C^{1,2}, Lu D^{1,2}, Grance M^{1,2}, Nowak G³, Lanteri C¹, Tribble D¹, Burgess TH¹

6
7 ¹Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics,
8 Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America

9 ²Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland,
10 United States of America

11 ³EpiData Center, Navy and Marine Corps Public Health Center, Portsmouth, Virginia, United States of
12 America

13
14 * Corresponding author

15 Email: spollett@idcrp.org

16

17

18 **Abstract**

19 **Background:** Understanding the risk of chikungunya virus (CHIKV) infection and rheumatic sequelae
20 across populations, including travelers and the military, is critical. We leveraged the electronic medical
21 records of about 9.5 million U.S. Military Health System (MHS) beneficiaries to identify the risk of post-
22 CHIKV rheumatic sequelae. **Methodology/Principal Findings:** MHS beneficiary CHIKV infections
23 diagnosed 2014–2018 were identified from the Disease Reporting System internet, TRICARE Encounter
24 Data Non-Institutional, and Comprehensive Ambulatory/Professional Encounter Record systems. Non-
25 CHIKV controls were matched (1:4) by age, gender, beneficiary status, and encounter date. The
26 frequency of comorbidities and incident rheumatic diagnoses through 2020 were derived from
27 International Classification of Diseases codes and compared between cases and controls. Logistic
28 regression models estimated the association of CHIKV infection with rheumatic sequelae and risk factors
29 for post-CHIKV sequelae. 195 CHIKV cases were diagnosed between July 2014 and December 2018. The
30 mean age was 42 years, and 43.6% were active duty. 63/195 (32.3%) of CHIKV cases had an incident
31 rheumatic diagnosis, including arthralgia, polyarthritis, polymyalgia rheumatica, and/or rheumatoid
32 arthritis, compared to 156/780 (20.0%) of controls ($p < 0.001$). CHIKV infection remained associated with
33 rheumatic sequelae (aOR = 1.911, $p = 0.002$) after adjusting for prior rheumatic disease and
34 demography. Those with rheumatic CHIKV sequelae had a median 7 healthcare encounters (IQR 3–15).
35 Among CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and
36 demography, service characteristics, or comorbidities. **Conclusions/Significance:** CHIKV infection is
37 uncommon but associated with rheumatic sequelae among MHS beneficiaries, with substantial
38 healthcare requirements in a proportion of cases with such sequelae. No demographic, clinical, or
39 occupational variables were associated with post-CHIKV rheumatic sequelae, suggesting that prediction
40 of these complications is challenging in MHS beneficiaries. These findings are important context for
41 future CHIKV vaccine decision making in this and other populations.

42 **Author summary:**

43 We examined U.S. Military Health System (MHS) electronic medical records during to identify the
44 likelihood of rheumatic complications after chikungunya virus (CHIKV) infection. Overall, CHIKV
45 infections were rare in the MHS, with 195 cases found in the records between 2014 and 2018 (a period
46 which encompassed the peak of the CHIKV epidemic in the Americas). Of these, about 32% received a
47 rheumatic diagnosis after infection, including arthralgia, polyarthritis, polymyalgia rheumatica, and
48 rheumatoid arthritis. Patients who had a rheumatic diagnosis had on average 7 healthcare encounters
49 for their post-CHIKV rheumatic complication, and a quarter had more than 15 healthcare encounters.
50 We did not find any demographic, clinical, or occupational characteristics associated with developing
51 rheumatic complications after CHIKV, suggesting that predicting rheumatic complications from CHIKV
52 may be challenging in MHS beneficiaries. These findings may provide important context for decisions
53 about implementing an approved chikungunya vaccine to military servicemembers and other MHS
54 beneficiaries.

55

56 **Introduction**

57 Chikungunya virus (CHIKV) is a mosquito-borne alphavirus belonging to the *Togaviridae* family [1]. The
58 ecology of CHIKV is characterized by a sylvatic cycle involving non-human primates and arboreal *Aedes*
59 species and urban human-to-human transmission cycles involving the *A. aegypti* and *A. albopictus*
60 vectors [1]. While CHIKV is defined by a single serotype, multiple genotypes have evolved with global
61 geographic expansion including the Asian and descendant Asian-Caribbean lineages, and
62 East/Central/South African and Indian Ocean lineages [1-3].

63

64 The 2013–2015 neotropical epidemic in the Americas involved over 1.6 million suspected or confirmed
65 CHIKV cases [4]. While cases rapidly declined after the initial neotropical pandemic, there is an ongoing
66 substantive CHIKV burden in the Americas in addition to ongoing circulation in Africa [5, 6] and Asia [7,
67 8]. Recently, the Pan American Health Organization issued an alert indicating the geographic range of
68 CHIKV has expanded in the Americas, with notable resurgence in certain regions of Latin America [9-11].
69
70 Acute CHIKV infection illness is characterized by a high symptomatic-to-asymptomatic ratio, with clinical
71 features including an abrupt onset of high fever, polyarthralgia, backache, headache, and fatigue [12].
72 Atypical acute CHIKV illness manifestations (e.g., acute encephalitis) are rare, potentially severe, and
73 more often occur in the extremes of age and in those with underlying comorbidities [12-17]. Diagnosis
74 of CHIKV infection relies on blood polymerase chain reaction (PCR) within the first week of illness and
75 serology thereafter [18]. Management of acute CHIKV is generally supportive, with fluid replacement,
76 analgesia and avoidance of non-steroidal anti-inflammatory drugs until dengue has been excluded as a
77 differential diagnosis [19]. There are no current vaccines or other preventive medical countermeasures
78 available for CHIKV aside from avoidance of vectors in endemic transmission regions [19]. Advanced
79 vaccine development has been challenging due to the unpredictable nature of CHIKV outbreaks [20].
80 However, CHIKV vaccine U.S. Food and Drug Administration licensure may soon occur using a serological
81 correlate of protection [21].

82
83 The rheumatological manifestations of CHIKV may be categorized by timing and clinical phenotype [22].
84 Acute CHIKV arthralgia is frequently reported and mostly occurs in mostly peripheral joints with a
85 symmetrical pattern, although large joints can be affected [22]. Joint swelling and synovitis often
86 accompanies this acute polyarthralgia; functional impairment during this acute phase is common due
87 debilitating pain [22]. Chronic rheumatological manifestations typically involve the joints affected in

88 acute CHIKV arthralgia [22]. Estimates on the frequency of persistent post-acute manifestations
89 (predominantly arthralgia or arthritis) vary significantly, with metanalysis estimates as high as 43% at 3
90 months, 21% at 12 months, and 14% at 18 months after initial CHIKV illness onset [22-24]. This
91 heterogeneity is believed to reflect differences in study populations and methodologies. Pathogenesis
92 studies have indicated that persistent host inflammation, rather than persistent synovial viral
93 replication, plays a key role in post-CHIKV arthralgia [25, 26]. There is currently a wide variation in
94 clinical management for chronic post-CHIKV sequelae [15] but post-acute CHIKV arthropathy is severe
95 enough in some to warrant the use of biological or disease-modifying antirheumatic drugs [27].

96
97 While those residing in CHIKV endemic regions experience the highest burden of this arbovirus, travelers
98 and the deploying military are also significant stakeholders for understanding the risk of CHIKV infection
99 and post-CHIKV sequelae. There is limited published data on the burden of CHIKV in U.S. Military Health
100 System (MHS) beneficiaries [28, 29] and none define the risk and risk factors of post-acute CHIKV
101 sequelae in this population. Understanding the risk and risk factors of CHIKV and CHIKV sequelae is
102 important for clinical prognostication and may support cost-effectiveness analyses for vaccine policy
103 with potential future licensed vaccines; such findings may be generalizable to traveler populations also.

104
105 The objectives in this study were to describe to characterize incident CHIKV cases that were diagnosed in
106 the MHS between 2014–2018 and to further describe the risk and risk factors of acute and chronic post-
107 CHIKV rheumatological sequelae in such CHIKV cases, compared to matched controls. Here, we
108 leveraged a virtual cohort derived from over 9.5 million MHS beneficiaries, with follow-up through 2020.

109

110 **Methods**

111 **Population, setting and identification of CHIKV cases and matched** 112 **controls**

113
114 The MHS serves approximately 9.5 million beneficiaries, including active duty servicemembers, retirees
115 and dependents. This includes care delivered within the United States, U.S. Territories (including Puerto
116 Rico, Guam, and the U.S. Virgin Islands), and in beneficiaries located other countries.

117
118 For this study, we identified deduplicated unique CHIKV cases in MHS beneficiaries via multiple data
119 streams from 2005 through 2018, including: (i) clinical microbiology lab (serology and PCR) results from
120 Disease Reporting System internet (DRSi)/EpiData Center, (ii) International Classification of Diseases,
121 10th Revision (ICD-10) code A92.0 CHIKV disease entries from TRICARE Encounter Data Non-Institutional
122 (TEDNI), and (iii) ICD-10 code A92.0 CHIKV disease from Comprehensive Ambulatory/Professional
123 Encounter Record (CAPER). The treatment locations of cases were inferred by clinical provider ZIP code.
124 To estimate the risk of post-CHIKV rheumatological sequelae, CHIKV negative MHS beneficiary controls
125 were matched (1:4) with cases by age group, gender, date of healthcare encounter (+/- 1 month), and
126 beneficiary status at the time of matching healthcare encounter. Controls were randomly selected
127 within these matching strata.

128 129 **Demographic, post-CHIKV diagnosis and comorbidity data abstraction** 130 **from the electronic medical record**

131 Demographic ICD-9 and ICD-10 code data abstracted from cases and controls (using Armed Forces
132 Health Longitudinal Technology Application (AHLTA) and the Composite Health Care System (CHCS). The
133 sequelae of interest were any rheumatologic disorders (See S1 Table for ICD-9 and ICD-10 codes). Co-
134 morbidity was defined as a condition/disorder (including rheumatological) which pre-existed before the
135 time of the first CHIKV infection diagnosis (or first matched healthcare encounter of the time-matched

136 control. We defined post-CHIKV rheumatological complications as new post-CHIKV rheumatological
137 diagnoses with a first onset at or after the first CHIKV diagnosis (or the healthcare encounter used for
138 matching for controls without CHIKV). When a pre-CHIKV rheumatological and post-CHIKV
139 rheumatological diagnosis mapped to the same ICD code, we further adjudicated a pre-existing
140 rheumatological diagnoses from a new post-CHIKV complication using DX_DESC-level diagnosis coding
141 (Agency for Healthcare Research and Quality Clinical Classifications Software system code). A similar
142 approach was taken for controls without CHIKV.

143

144 **Statistical analysis**

145 Demographic, clinical, and occupational characteristics of cases and controls were summarized. The
146 frequency of rheumatological sequelae were compared in cases and controls. Conditional logistic
147 regression (on age and sex matched cases and controls) were used to estimate the independent
148 association between CHIKV infection and short-term (<3 months) versus long-term (≥ 3 months)
149 complications, adjusting for prior comorbidities (including pre-existing rheumatological comorbidities).
150 Unadjusted and adjusted odds ratios were presented. Finally, among those with CHIKV infections, we
151 performed multinomial regression for any to determine risk factors for any rheumatologic related
152 sequelae. For each multinomial regression analysis, there were 3 comparisons: participants with short-
153 term (<3 months), long-term (≥ 3 months) and no sequelae.

154

155 All p values were two-sided, with an alpha significance threshold of 0.05. Analyses were conducted using
156 SAS software (version 9.4; SAS).

157

158 **Ethical considerations**

159 This protocol was reviewed and approved for execution by the IRB of the Uniformed Services University
160 of the Health Sciences, Bethesda, Maryland, United States of America.

161

162 **Results**

163 We identified 195 unique CHIKV cases diagnosed in the MHS between July 2014 and December 2018 (S1
164 Fig). The most frequent locations of clinical encounters were in Puerto Rico, Texas, and California, but
165 these reflect provider ZIP codes of diagnoses (including potential diagnoses made after deployments or
166 other beneficiary travel) and do not necessarily reflect location of where cases acquired CHIKV infections
167 (Fig 1). Our finding of the majority of cases being diagnosed in Puerto Rico agreed with prior, smaller
168 studies in MHS beneficiaries [29, 30]. Time series of all MHS CHIKV cases (by month) indicated the peak
169 of MHS CHIKV cases occurring in late 2014 during the peak year of the Americas CHIKV epidemic.

170

171 **Fig 1. Location of CHIKV cases by U.S. state or territory.**

172

173 The median age of CHIKV cases was 42 years (IQR 31–54 years), and 43.6% were active duty
174 servicemembers (Table 1). Compared to age, gender, beneficiary status, and healthcare encounter-
175 matched controls, cases differed from controls with respect to race ($p < 0.001$). Among active duty
176 CHIKV cases, we noted that Army service and enlisted rank were most frequent; the frequency of these
177 categories were more common than matched controls ($p < 0.001$; Table 1). CHIKV cases had a higher
178 frequency of all measured comorbidities compared to age, sex, and beneficiary-matched controls ($p <$
179 0.001 ; Table 2).

180

181 **Table 1. Demographic and professional characteristics in CHIKV cases and controls.**

	CHIKV negative controls ^a	CHIKV cases	Total	p value ^b
--	-----------------------------------------	-------------	-------	----------------------

No. of subjects (N)	780	195	975	
Characteristic	n (n/N %)	n (n/N %)	n (n/N %)	
Gender				>.9999
Male	412 (52.82)	103 (52.82)	515 (52.82)	
Female	368 (47.18)	92 (47.18)	460 (47.18)	
Age, median, [Q1–Q3]	41 [29–56]	42 [31–54]	41 [30–55]	0.6026
Age				>.9999
≤25	84 (10.77)	21 (10.77)	105 (10.77)	
26–35	204 (26.15)	51 (26.15)	255 (26.15)	
36–45	190 (24.36)	48 (24.62)	238 (24.41)	
46–64	204 (26.15)	51 (26.15)	255 (26.15)	
65+	98 (12.56)	24 (12.31)	122 (12.51)	
Race				<.0001
White	321 (41.15)	113 (57.95)	434 (44.51)	
Black	55 (7.05)	12 (6.15)	67 (6.87)	
Asian or Pacific Islander	23 (2.95)	12 (6.15)	35 (3.59)	
Other	21 (2.69)	30 (15.38)	51 (5.23)	
Unknown	360 (46.15)	28 (14.36)	388 (39.79)	
Beneficiary				>.9999
Active duty	340 (43.59)	85 (43.59)	425 (43.59)	
Dependent	108 (13.85)	27 (13.85)	135 (13.85)	
Retiree	80 (10.26)	20 (10.26)	100 (10.26)	
Others	252 (32.31)	63 (32.31)	315 (32.31)	
Service branch^c				<.0001
Air Force	189 (24.23)	8 (4.10)	197 (20.21)	
Army	76 (9.74)	51 (26.15)	127 (13.03)	
Coast Guard	8 (1.03)	23 (11.79)	31 (3.18)	
Other	67 (8.59)	3 (1.54)	70 (7.18)	
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)	

Rank	<.0001		
Enlisted	233 (29.87)	69 (35.38)	302 (30.97)
Officer	107 (13.72)	16 (8.21)	123 (12.62)
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)

182 ^aControls were matched with cases by age group, gender, beneficiary and date of encounter (+/- 1 month).

183 ^bp-values are calculated from a Chi-squared/Fisher's exact test or Kruskal-Wallis test, as appropriate.

184 ^cService branch and rank are only available for active duty. Other non-active duty subjects are grouped under "Not
185 applicable" category.

186

187 **Table 2. Comorbidities in CHIKV cases and controls.**

	CHIK-	CHIK+	Total	p value ^a
Total # of subjects	780	195	975	
Comorbidities (ICD diagnoses before time of matching)				
None	461 (59.10)	34 (17.44)	495 (50.77)	<.0001
Cancer	30 (3.85)	22 (11.28)	52 (5.33)	<.0001
Cardiovascular disease	196 (25.13)	95 (48.72)	291 (29.85)	<.0001
Chronic respiratory disease	91 (11.67)	58 (29.74)	149 (15.28)	<.0001
Mental health condition	117 (15.00)	72 (36.92)	189 (19.38)	<.0001
Osteoporosis	26 (3.33)	19 (9.74)	45 (4.62)	0.0001
Upper gastrointestinal disease	103 (13.21)	75 (38.46)	178 (18.26)	<.0001
Neurologic disease	122 (15.64)	80 (41.03)	202 (20.72)	<.0001
Rheumatologic disease	117 (15.00)	84 (43.08)	201 (20.62)	<.0001
Osteoarthritis	92 (11.79)	55 (28.21)	147 (15.08)	<.0001
Other non-traumatic joint disorders	29 (3.72)	32 (16.41)	61 (6.26)	<.0001
Rheumatoid arthritis and related disease	12 (1.54)	17 (8.72)	29 (2.97)	<.0001
Spondylosis; disc disorders; other back problems	51 (6.54)	37 (18.97)	88 (9.03)	<.0001

188 ^ap values were calculated from a Chi-squared/Fisher's exact test.

189
 190 We noted 63/195 (32.3%) of CHIKV cases had an incident post-CHIKV rheumatological diagnosis,
 191 compared to 156/780 (20.0%) of controls ($p = 0.0002$) (Table 3). Osteoarthritis, rheumatoid arthritis and
 192 related diagnoses (including inflammatory polyarthropathy), and non-traumatic joint disorder associated
 193 categories (including unspecified arthropathy, polyarthralgia and polyarthritits) were noted with
 194 statistically significant higher frequency in post-CHIKV cases versus controls (Table 3, S2 Table).

195

196 **Table 3. Rheumatological sequelae in CHIKV cases and controls.**

	CHIK-	CHIK+	Total	p value ^a
No. of subjects	780	195	975	
Any rheumatic sequelae^b	156 (20.00)	63 (32.31)	219 (22.46)	0.0002
Rheumatic sequelae by category^c				
Infective arthritis and osteomyelitis	0 (0.00)	1 (0.51)	1 (0.10)	0.2000
Malaise and fatigue	59 (7.56)	18 (9.23)	77 (7.90)	0.4402
Osteoarthritis	2 (0.26)	4 (2.05)	6 (0.62)	0.0166
Other connective tissue disease	12 (1.54)	4 (2.05)	16 (1.64)	0.5404
Other non-traumatic joint disorders	17 (2.18)	21 (10.77)	38 (3.90)	<.0001
Other screening for suspected conditions	81 (10.38)	24 (12.31)	105 (10.77)	0.4384
Rheumatoid arthritis and related disease	2 (0.26)	7 (3.59)	9 (0.92)	0.0003

197 ^ap values were calculated from a Chi-squared/Fisher's exact test.

198 ^bSubject with more than one diagnosis code were only counted once.

199 ^cCCS_DX_DESC category, subject may have multiple diagnosis with different categories.

200

201 Compared to controls, CHIKV infection was associated with post-infection rheumatological diagnoses
 202 (aOR = 1.91, 95% CI 1.272–2.870, $p = 0.0018$) after adjusting for prior the presence of any prior pre-
 203 CHIKV rheumatological diagnoses, beneficiary status, age, sex, and race (Table 4). The magnitude of this

204 effect size was larger when the outcome was stratified into short-term (≤ 3 month) post-CHIKV
 205 rheumatological diagnoses versus long-term (diagnosis recurred beyond 3 months post-CHIKV infection)
 206 rheumatic sequelae (aOR = 6.41, $p < 0.001$ short-term sequelae; aOR = 1.43, $p = 0.09$ long-term
 207 sequelae, respectively) (Table 5). Those with post-CHIKV rheumatological sequelae had a median 7
 208 healthcare encounters for rheumatological diagnoses (IQR 3–15, range 1–33) through the period of
 209 observation.

210

211 **Table 4. Unadjusted and adjusted odds ratio of CHIKV infection on rheumatic-related sequelae (n =**
 212 **975).**

	Unadjusted				Adjusted ^a			
	OR	95 % CI	p value	OR	95% CI	p value		
CHIK positive	1.909	1.348	2.703	0.0003	1.911	1.272	2.870	0.0018
Rheumatic related comorbidity	1.609	1.134	2.283	0.0078	1.137	0.763	1.695	0.5283
Age	1.011	1.002	1.019	0.0107	1.012	1.002	1.022	0.0181
Male	0.984	0.728	1.330	0.9171	0.918	0.620	1.358	0.6669
Race (ref: White)								
Black	1.062	0.580	1.944	0.8464	1.178	0.633	2.192	0.6055
Asian or Pacific Islander	0.846	0.359	1.995	0.7024	0.758	0.314	1.830	0.3551
Other	0.960	0.698	1.319	0.8001	1.294	0.846	1.977	0.2307
Beneficiary (ref: active duty)								
Dependents of active duty	0.591	0.353	0.990	0.0458	— ^a			
Retirees	0.752	0.435	1.301	0.3084	— ^a			
Others	1.056	0.752	1.483	0.7541	— ^a			
Service branch (ref: Air Force)								
Army	2.088	1.266	3.444	0.0039	1.582	0.930	2.691	0.0004
Coast Guard	0.564	0.187	1.702	0.3092	0.360	0.113	1.143	0.1017
Other	0.709	0.342	1.472	0.3565	0.686	0.328	1.437	0.7368

Not applicable (non-active duty)	1.039	0.697	1.550	0.8501	0.640	0.379	1.080	0.4056
Rank (ref: enlisted)								
Officer	1.600	0.996	2.571	0.0518	— ^a			
Not applicable (non-active duty)	1.016	0.721	1.431	0.9287	— ^a			

213 ^aBeneficiary and rank are not included in the adjusted model due to collinearity with service branch.

214

215 **Table 5. Adjusted odds ratio on rheumatic-related short-term and long-term sequelae (n = 975).**

	Short-term (<3 month)			Long-term (≥3 month)				
	OR	95% CI	p value	OR	95% CI	p value		
CHIK positive	6.410	2.904	14.152	<.0001	1.428	0.947	2.153	0.0894
Rheumatic-related comorbidity	0.616	0.242	1.567	0.3087	1.329	0.878	2.012	0.1789
Age	1.018	0.997	1.040	0.0991	1.008	0.998	1.018	0.0989
Male	1.053	0.469	2.365	0.9011	1.071	0.731	1.569	0.7247
Race (ref: white)								
Black	1.118	0.238	5.243	0.8593	1.093	0.573	2.085	0.5557
Asian or Pacific Islander	1.614	0.336	7.748	0.6634	0.702	0.261	1.882	0.4449
Other	1.314	0.542	3.186	0.8761	1.002	0.668	1.501	0.7193

216 *Note:* 1) “No Rheumatic related sequelae” is consider as reference group for the outcome variable. 2) “Service” is
 217 excluded from the adjusted model due to quasi-complete separation of data points.

218

219 Among those with CHIKV infections, we found no association between post-CHIKV rheumatic sequelae

220 and age, sex, race, active-duty status, or pre-existing comorbidities. Non-Army service branch and

221 female sex was associated with a reduced odds of post-CHIKV rheumatological sequelae, but this was

222 not statistically significant (Table 6).

223

224 **Table 6. Unadjusted and adjusted odds ratio on rheumatic-related sequelae among people with CHIK**
 225 **infection (n = 195).**

	Unadjusted				Adjusted			
	OR	95% CI	p value		OR	95% CI	p value	
Age	1.002	0.985	1.020	0.8156	1.006	0.978	1.034	0.6969
Male (ref: female)	0.974	0.534	1.777	0.9323	0.679	0.288	1.599	0.3751
Race (ref: white)								
Black	0.685	0.175	2.680	0.5865	0.624	0.138	2.816	0.4970
Asian or Pacific Islander	1.467	0.436	4.935	0.5356	1.350	0.376	4.853	0.4577
Other	0.924	0.468	1.826	0.8208	0.866	0.397	1.888	0.8440
Service branch (ref: Army)								
Coast Guard	0.256	0.076	0.860	0.0276	0.275	0.077	0.979	0.0917
Other	1.461	0.395	5.407	0.5703	1.566	0.406	6.042	0.0634
Not applicable (non-active duty)	0.457	0.228	0.913	0.0266	0.341	0.141	0.828	0.0922
Comorbidities								
Cancer	0.975	0.376	2.526	0.9586	1.029	0.324	3.269	0.9618
Cardiovascular disease	0.937	0.514	1.709	0.8320	0.799	0.371	1.720	0.5659
Chronic respiratory disease	1.431	0.751	2.725	0.2757	1.902	0.841	4.300	0.1226
Mental health condition	0.974	0.523	1.815	0.9339	0.889	0.420	1.881	0.7575
Osteoporosis	1.250	0.467	3.346	0.6569	1.488	0.390	5.680	0.5609
Upper gastrointestinal disease	0.977	0.527	1.812	0.9422	0.988	0.482	2.024	0.9737
Neurologic disease	0.757	0.408	1.403	0.3762	0.657	0.300	1.439	0.2941
Rheumatologic	1.086	0.593	1.988	0.7899	0.985	0.472	2.059	0.9688

226 *Note:* Service branch was regrouped to avoid quasi-complete separation. Other includes: Air Force and others.
 227

228 **Conclusion**

229 Understanding the risk of CHIKV infection and complications in deploying U.S. military servicemembers
 230 and other MHS beneficiaries is important, particularly with upcoming possible CHIKV vaccine licensure.

231 We found a very low number of CHIKV cases identified in the MHS, despite this study period covering
232 the peak CHIKV epidemic in the Americas and leveraging data from about 9.5 million beneficiaries. Our
233 findings correlate with low number of CHIKV infections in other U.S. MHS studies, although such studies
234 were either smaller, earlier in the CHIKV epidemic and/or less comprehensive in their use of electronic
235 medical record (eMR) data sources [28, 31]. Additionally, our findings correlate with a recent post-
236 deployment serology study of 1500 deployments to South America and Puerto Rico with a low post-
237 deployment seropositivity rate of 1.7% (highest in those serving in Puerto Rico) [32]. Our findings further
238 agree with studies in other armed forces which also note a low frequency of CHIKV infections [28].

239
240 These low frequencies of infection may be attributed to effective personal mosquito avoidance or
241 heterogeneity in risk exposure (for example, based on deployment role) when deployed or activated in
242 CHIKV endemic countries or territories. Among CHIKV infections in servicemembers, we noted higher
243 frequency Army service and enlisted ranks compared to matched servicemember controls without
244 CHIKV; these groups have previously been noted at higher risk for other arboviruses [33, 34]. While the
245 location of diagnosis may not reflect where the infection was acquired, the highest number of cases
246 were diagnosed in Puerto Rico is consistent with the known high transmission of CHIKV during the
247 neotropical epidemic [35].

248
249 While the overall number of infections was very low, we found a substantive risk of post-CHIKV
250 rheumatological complications. We noted a considerable burden of disease with a median 7 healthcare
251 encounters for this complication, and 25% of these complicated CHIKV cases required between 15 and
252 33 further encounters through the period of observation. These findings highlight that, while CHIKV
253 infections are overall rare in MHS beneficiaries, patient morbidity in complicated CHIKV cases can be
254 substantial, as noted in non-MHS studies [22].

255
256 The overall low number of CHIKV infections limited statistical power for examining risk factors for post-
257 CHIKV sequelae. We found a non-statistically significant trend toward Army and male sex having a
258 higher risk of rheumatic complications, but no other predictors were noted, including pre-existing
259 comorbidities. Further study of cumulative CHIKV infections in MHS-based virtual cohorts over time may
260 identify clearer risk factors for this complication, and this may assist in more precise prognostication of
261 CHIKV cases in the MHS. As this study comprises the largest number of CHIKV infections in any military
262 study, we would conclude that prediction of MHS CHIKV cases may progress to complicated
263 rheumatological sequelae remains challenging, underscoring the need for optimal prevention of CHIKV
264 infection.

265
266 There were several strengths to this study. The use of the MHS includes a substantive number of
267 beneficiaries who deploy or are stationed in CHIKV endemic regions and allowed for long term follow-up
268 of cases to determine longer term complications. We derived CHIKV cases from a range of eMR data
269 sources, including clinical microbiology laboratory results, to identify more infections than prior MHS-
270 based studies [28-31]. Our study limitations included the use of ICD codes to diagnose CHIKV and post-
271 CHIKV complications; prior evaluations of CHIKV ICD diagnosis coding have noted imperfect specificity
272 [31] and this study was unable to perform chart adjudications. Conversely, CHIKV diagnoses may have
273 been missed in some clinical presentations, and not all cases may have presented to care (including
274 during deployments).

275
276 Future directions include further studies which could also examine for non-rheumatological CHIKV
277 sequelae such as neurocognitive complications, mood, and long-term functional impact (for example,
278 [36, 37]). Finally, studies could leverage sera routinely collected from the U.S. military servicemembers

279 and used for arboviral research (i.e., the Department of Defense Sera Repository [32-34]) to identify
280 prognostic and treatment related biomarkers for those beneficiaries with persistent post-CHIKV
281 sequelae, as well as enabling ongoing serosurveillance of the risk and risk factors of CHIKV in deployed
282 military, particularly during an era of increasing CHIKV risk in the Americas [9].

283

284 **Disclaimer**

285 The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect
286 the views, opinions, or policies of Uniformed Services University of the Health Sciences; the Department
287 of Defense; the Departments of the Army, Navy, or Air Force; the Defense Health Agency; the National
288 Institutes of Health, the Department of Health and Human Services or the Henry M. Jackson Foundation
289 for the Advancement of Military Medicine, Inc. Mention of trade names, commercial products, or
290 organizations does not imply endorsement by the U.S. government. The investigators have adhered to
291 the policies for protection of human subjects as prescribed in 45 CFR 46.

292

293 **Funding statement**

294 The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of
295 Defense program executed by the Uniformed Services University of the Health Sciences through a
296 cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine,
297 Inc.. This project has been funded in part by the National Institute of Allergy and Infectious Diseases at
298 the National Institutes of Health, under an interagency agreement (Y1-AI-5072); and the Military
299 Infectious Diseases Research Program. The authors declare no conflicts of interest.

300

301 **References**

- 302 1. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a
303 vaccine. *Expert Rev Vaccines*. 2012;11(9): 1087-1101. pmid:23151166
- 304 2. Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. *Antiviral*
305 *Res*. 2015;120: 32-39. pmid:25979669
- 306 3. Rezza G, Weaver SC. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease
307 impact and hurdles to vaccine development. *PLoS Negl Trop Dis*. 2019;13(1): e0006919.
308 pmid:30653504
- 309 4. 54th Directing Council. Report on chikungunya virus transmission and its impact in the region of the
310 Americas. 67th Session of the Regional Committee of WHO for the Americas; September 28 to
311 October 2, 2015; Washington, DC: Pan American Health Organization and World Health
312 Organization Regional Office for the Americas. Available from:
313 <https://www3.paho.org/hq/dmdocuments/2015/CD54-INF-3-e.pdf>
- 314 5. Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of
315 dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. *IJID Reg*. 2022;5: 68-
316 71. pmid:36200059
- 317 6. Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden
318 burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. *Int J Environ Res*
319 *Public Health*. 2022;19(15): 8896. pmid:35897268
- 320 7. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global
321 epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the
322 development and introduction of vaccines. *PLoS Negl Trop Dis*. 2022;16(1): e0010069.
323 pmid:35020717

- 324 8. Pan American Health Organization, World Health Organization. Cases of chikungunya virus disease.
325 2023. Available from: [https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-
327 weekly-en.html](https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-
326 weekly-en.html)
- 327 9. Centers for Disease Control and Prevention. Increased chikungunya virus activity in Paraguay and
328 associated risk to travelers. 2023. Available from:
329 <https://emergency.cdc.gov/han/2023/han00487.asp>
- 330 10. Pan American Health Organization, World Health Organization. Epidemiological alert: Chikungunya
331 increase in the region of the Americas. 2023. Available from:
332 <https://www.paho.org/en/documents/epidemiological-alert-chikungunya-increase-region-americas>
- 333 11. Pan American Health Organization, World Health Organization. Epidemiological alert: Increase in
334 cases and deaths from chikungunya in the region of the Americas. 2023. Available from:
335 [https://www.paho.org/en/documents/epidemiological-alert-increase-cases-and-deaths-
336 chikungunya-region-americas](https://www.paho.org/en/documents/epidemiological-alert-increase-cases-and-deaths-
336 chikungunya-region-americas)
- 337 12. Centers for Disease Control and Prevention. Clinical evaluation and disease. 2023. Available from:
338 <https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html>
- 339 13. de Moraes Alves Barbosa Oliveira R, Kalline de Almeida Barreto F, Praça Pinto G, Timbó Queiroz I,
340 Montenegro de Carvalho Araújo F, Wanderley Lopes K, et al. Chikungunya death risk factors in
341 Brazil, in 2017: A case-control study. PLoS One. 2022;17(4): e0260939. pmid:35389992
- 342 14. Sharp TM, Keating MK, Shieh WJ, Bhatnagar J, Bollweg BC, Levine R, et al. Clinical characteristics,
343 histopathology, and tissue immunolocalization of chikungunya virus antigen in fatal cases. Clin
344 Infect Dis. 2021;73(2): e345-e354. pmid:32615591
- 345 15. Webb E, Michelen M, Rigby I, Dagens A, Dahmash D, Cheng V, et al. An evaluation of global
346 Chikungunya clinical management guidelines: A systematic review. EClinicalMedicine. 2022;54:
347 101672. pmid:36193172

- 348 16. Pescarini JM, Rodrigues M, Paixão ES, Cardim L, Brito CAA, Costa MDCN, et al. Dengue, Zika, and
349 chikungunya viral circulation and hospitalization rates in Brazil from 2014 to 2019: An ecological
350 study. *PLoS Negl Trop Dis*. 2022;16(7): e0010602. pmid:35895718
- 351 17. Chee YS, Ahamad Fouzi N, Chong YM, Sam IC, Chan YF, Chua CL, et al. Chikungunya encephalopathy
352 and pneumonia in a young infant presenting with septic shock. *J Paediatr Child Health*. 2022;58(8):
353 1468-1471. pmid:35175651
- 354 18. Centers for Disease Control and Prevention. Diagnostic testing. 2023. Available from:
355 <https://www.cdc.gov/chikungunya/hc/diagnostic.html>
- 356 19. Centers for Disease Control and Prevention. Treatment and Prevention. 2023. Available from:
357 <https://www.cdc.gov/chikungunya/hc/treatment-prevention.html>
- 358 20. Tran QM, Soda J, Siraj A, Moore S, Clapham H, Perkins TA. Expected endpoints from future
359 chikungunya vaccine trial sites informed by serological data and modeling. *Vaccine*. 2023;41(1):
360 182-192. pmid:36424258
- 361 21. Hills S. Overview of chikungunya and chikungunya vaccines. Meeting of the Advisory Committee on
362 Immunization Practices (ACIP); October 19-20, 2022; Atlanta, Georgia: Centers for Disease Control
363 and Prevention.
- 364 22. Suhrbier A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. *Nat*
365 *Rev Rheumatol*. 2019;15(10): 597-611. pmid:31481759
- 366 23. Rodríguez-Morales AJ, Cardona-Ospina JA, Urbano-Garzón SF, Hurtado-Zapata JS. Prevalence of
367 post-chikungunya infection chronic inflammatory arthritis: A systematic review and meta-analysis.
368 *Arthritis Care Res (Hoboken)*. 2016;68(12): 1849-1858. pmid:27015439
- 369 24. Paixão ES, Rodrigues LC, Costa MDCN, Itaparica M, Barreto F, Gerardin P, et al. Chikungunya chronic
370 disease: a systematic review and meta-analysis. *Trans R Soc Trop Med Hyg*. 2018;112(7): 301-316.
371 pmid:30007303

- 372 25. Sengupta S, Bhattacharya N, Tripathi A. Increased CRP, anti-CCP antibody, IL-2R, COMP levels in
373 prognosis of post-chikungunya chronic arthritis and protective role of their specific genotypes
374 against arthritic manifestation. *Virus Res.* 2022;323: 198998. pmid:36356677
- 375 26. Dobbs JE, Tritsch SR, Encinales L, Cadena A, Suchowiecki K, Simon G, et al. Regulatory T-cells and
376 GARP expression are decreased in exercise-associated chikungunya viral arthritis flares. *Front*
377 *Immunol.* 2022;13: 1007106. pmid:36275717
- 378 27. Ranzolin A, Marques CDL, da Rocha Junior LF, Duarte ALBP, de Lima HD, de Almeida Martins LM, et
379 al. Treatment with biological therapy is associated with faster recovery and lower frequency of
380 treatment switch among rheumatic patients with chikungunya fever. *Adv Rheumatol.* 2022;62(1):
381 44. pmid:36376923
- 382 28. Frickmann H, Herchenröder O. Chikungunya virus infections in military deployments in tropical
383 settings—a narrative minireview. *Viruses.* 2019;11(6): 550. pmid:31197085
- 384 29. Writer JV, Hurt L. Chikungunya infection in DoD healthcare beneficiaries following the 2013
385 introduction of the virus into the Western Hemisphere, 1 January 2014 to 28 February 2015.
386 *MSMR.* 2015;22(10): 2-6. pmid:26505074
- 387 30. O'Donnell FL, Stahlman S, Fan M. Surveillance for vector-borne diseases among active and reserve
388 component service members, U.S. Armed Forces, 2010-2016. *MSMR.* 2018;25(2): 8-15.
389 pmid:29485891
- 390 31. Wellington T, Fraser JA, Kuo HC, Hickey PW, Lindholm DA. The burden of arboviral infections in the
391 Military Health System 2012-2019. *Am J Trop Med Hyg.* 2023;108(5): 1007-1013. pmid:37037439
- 392 32. Pollett S, Lanteri C, Forshey B, Trefry S, Winkelmann E, Nasar F, et al. Serosurveillance of
393 chikungunya infections among U.S. military personnel deploying in the Americas, 2013-2020.
394 *ASTMH 71st Annual Meeting*; October 30 to November 3, 2022; Seattle, Washington: American
395 Society of Tropical Medicine and Hygiene. Available from:

396 [https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-](https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf)
397 [Meeting-Abstract-Book.pdf](https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf)

- 398 33. Pollett S, Kuklis CH, Barvir DA, Jarman RG, Romaine RM, Forshey BM, et al. The seroepidemiology of
399 dengue in a US military population based in Puerto Rico during the early phase of the Zika
400 pandemic. *PLoS Negl Trop Dis.* 2022;16(1): e0009986. pmid:35061659
- 401 34. Hesse EM, Martinez LJ, Jarman RG, Lyons AG, Eckels KH, De La Barrera RA, et al. Dengue virus
402 exposures among deployed U.S. military personnel. *Am J Trop Med Hyg.* 2017;96(5): 1222-1226.
403 pmid:28193746
- 404 35. Sharp TM, Roth NM, Torres J, Ryff KR, Pérez Rodríguez NM, Mercado C, et al. Chikungunya cases
405 identified through passive surveillance and household investigations—Puerto Rico, May 5-August
406 12, 2014. *MMWR Morb Mortal Wkly Rep.* 2014;63(48): 1121-1128. pmid:25474032
- 407 36. Peixoto VGMNP, Azevedo JP, Luz KG, Almondes KM. Cognitive dysfunction of chikungunya virus
408 infection in older adults. *Front Psychiatry.* 2022;13: 823218. pmid:35449568
- 409 37. Doran C, Elsinga J, Fokkema A, Berenschot K, Gerstenbluth I, Duits A, et al. Long-term chikungunya
410 sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curacao. *PLoS*
411 *Negl Trop Dis.* 2022;16(3): e0010142. pmid:35231033

412

413 **Supporting information**

414 **S1 Fig. Chikungunya virus case identification from U.S. Military Health System electronic medical**
415 **record systems.** TEDNI—TRICARE Encounter Data Non-Institutional; CAPER—Comprehensive
416 Ambulatory/Professional Encounter Record.

417

418 **S1 Table. International Classification of Diseases, 9th Revision (ICD-9) and ICD-10 codes (including**
419 **cross-walked ICD-9 codes) used to identify rheumatological healthcare encounters in cases and**
420 **controls.**

421

422 **S2 Table. Long description of rheumatological healthcare encounters by chikungunya virus (CHIKV)**
423 **infection status.**

Fig 1.

